Martin Madaus - Feb 6, 2023 Form 4 Insider Report for REPLIGEN CORP (RGEN)

Role
Director
Signature
/s/ Kimberly Brown (Attorney in Fact)
Stock symbol
RGEN
Transactions as of
Feb 6, 2023
Transactions value $
$0
Form type
4
Date filed
2/8/2023, 06:24 PM
Previous filing
Jan 4, 2023
Next filing
Feb 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGEN Common Stock Award $0 +111 $0.00 111 Feb 6, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGEN Stock Option (Right to Buy) Award $0 +239 $0.00 239 Feb 6, 2023 Common Stock 239 $192.02 Direct F2
transaction RGEN Stock Option (Right to Buy) Award $0 +1.82K $0.00 1.82K Feb 6, 2023 Common Stock 1.82K $192.02 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Mr. Madaus was awarded 111 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on May 18, 2023, the date of the annual meeting of the Company's shareholders. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2 Award vests in full on May 18, 2023, the date of the annual meeting of the Company's shareholders.
F3 The shares vest in equal annual instalments over a three-year period with each such vesting date occurring on the earlier of the anniversary of the grant date or the date of the annual meeting of the Company's shareholders of the applicable year of such three-year period.